Evidence map›Paper›PMID 30758843›Full record

ReviewThe British journal of dermatology2019

Disease trajectories in childhood atopic dermatitis: an update and practitioner's guide.

A D Irvine, P Mina-Osorio

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in The British journal of dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05719649 (The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis - A Double-blind, Multi-center Randomized, Placebo-controlled Clinical Trial), which is not on this map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05719649 naunknown statusnot on this mapstarted 2023, after this paper: background citation

The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis - A Double-blind, Multi-center Randomized, Placebo-controlled Clinical Trial

TypeinterventionalSponsorSunWay Biotech Co., LTD.Ran2023 to 2023Enrolled72ConditionsAtopic Dermatitis, Atopic Dermatitis EczemaArmsLactic acid bacteria NTU 101, Placebo
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Observational
  6. The journal of allergy and clinical immunology. Global · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. The role of microRNAs in atopic dermatitis.Non-coding RNA research · 2024
    Review
  11. Article
  12. Article
  13. Review
  14. Treat-to-Target in Atopic Dermatitis.American journal of clinical dermatology · 2024
    Review
  15. Article
  16. Review
  17. Article
  18. Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis.JID innovations : skin science from molecules to population health · 2022
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

A D IrvinePaediatric Dermatology, Our Lady's Children's Hospital, Crumlin, Dublin, 12, Ireland.ORCID 0000-0002-9048-2044
P Mina-OsorioRegeneron Pharmaceuticals, Inc., Tarrytown, NY, U.S.A.ORCID 0000-0003-2986-9642
Regeneron (United States) · USTrinity College Dublin · IE

Funding

Regeneron Pharmaceuticals
6 · The paper itself

Abstract

backgroundAtopic dermatitis (AD) is a heterogeneous disease with a multifactorial aetiology and complex pathophysiology. This heterogeneity translates into different trajectories of disease progression with respect to severity, persistence and risk of development of atopic comorbidities. Determining which possible disease trajectories or comorbidities any individual child might develop is challenging in clinical practice. Tools that help identify paediatric patients at higher risk of disease progression would greatly aid clinicians.

methodsWe reviewed recent cohort studies to synthesize and simplify the epidemiological data to try to identify shared clinically relevant characteristics that may help physicians estimate the risk of disease progression in paediatric patients with AD.

resultsDespite the variability in data collection and methods of analysis and their limitations, there are common patterns of early-childhood AD that may aid in the estimation of risk for disease progression. Factors associated with risk of AD progression include younger age of onset, family history of atopy, greater AD severity, filaggrin mutations, urban environment and polysensitization and/or allergic multimorbidity. Based on these factors, we provide a practitioner's guide for identifying, counselling and/or referring infants and children with AD at potentially higher risk of developing persistent AD and atopic comorbidities. We also present clinical scenarios to illustrate how these data relate to real-life situations.

conclusionsUseful insights are provided for physicians and patients to inform them better about the risk of AD progression and to help guide care pathways for the paediatric population with AD. What's already known about this topic? The complex pathophysiology of atopic dermatitis (AD) translates into a heterogeneous clinical presentation and trajectories of disease progression. Although the consensus is that most paediatric patients with AD will eventually 'outgrow' the disease or follow the longitudinal trajectory known as the 'atopic march', a significant proportion will develop persistent AD and/or other atopic conditions. No known factors conclusively predict the risk of progression or development of comorbidities. What does this study add? Recent analyses of data from large cohorts of paediatric patients with AD have suggested the existence of potentially discrete clusters of patients who present with relatively common AD phenotypes. These studies have shed some light onto the factors associated with risk of progression, which we review in this article. A practitioner's guide with clinical scenarios is provided to help identify patients at high risk of progression to determine whether a patient should be monitored and/or would require specialist referral.

Indexed as

Practice Guidelines as TopicAge FactorsChildComorbidityDermatitis, AtopicDermatologyDisease ProgressionFilaggrin ProteinsHumansRisk FactorsSeverity of Illness IndexFilaggrin Proteins

Identifiers

PMID30758843
PMCPMC6899789
OpenAlexW2914269654

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.